Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical trial of KX2 391 for skin disorders.

Trial Profile

Clinical trial of KX2 391 for skin disorders.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2019

At a glance

  • Drugs Tirbanibulin (Primary)
  • Indications Psoriasis; Skin disorders
  • Focus Adverse reactions
  • Sponsors PharmaEssentia Corporation
  • Most Recent Events

    • 06 Jun 2019 Preliminary results from a cohort of patients with psoriasis (n=6) presented in an Athenex media release.
    • 15 Dec 2015 Status changed from planning to recruiting, as per Athenex media release.
    • 05 Dec 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top